Tag: Pharma acquisition news

AbbVie to acquire Cerevel Therapeutics for $8.7bn to expand neuroscience research

businessnewstoday- December 7, 2023

AbbVie Inc. (NYSE: ABBV) and Cerevel Therapeutics (NASDAQ: CERE) have announced a definitive agreement in which AbbVie will acquire Cerevel Therapeutics. The transaction, valued at ... Read More

Roche to acquire Carmot Therapeutics to expand obesity treatment portfolio

businessnewstoday- December 6, 2023

Roche announced its definitive agreement to acquire Carmot Therapeutics, Inc., based in Berkeley, California, for an upfront purchase price of USD 2.7 billion, with additional ... Read More

AbbVie to acquire ImmunoGen for $10.1bn to expand oncology portfolio

businessnewstoday- December 1, 2023

AbbVie Inc. and ImmunoGen Inc. have entered into a definitive agreement, marking a significant move in the pharmaceutical industry. AbbVie will acquire ImmunoGen, including its ... Read More

Boehringer Ingelheim expands oncology portfolio with T3 Pharma acquisition

businessnewstoday- November 22, 2023

Boehringer Ingelheim announced its acquisition of T3 Pharmaceuticals AG (“T3 Pharma”), a Swiss biotech company specializing in immuno-oncology, for up to 450 million CHF. T3 ... Read More

Merck to acquire Caraway Therapeutics in $610m deal for neurodegenerative disease treatments

businessnewstoday- November 22, 2023

Merck and Caraway Therapeutics, Inc. have announced a definitive agreement in which Merck, through a subsidiary, will acquire Caraway Therapeutics. The total potential consideration for ... Read More

Roche announces $7.1bn deal to acquire Telavant and RVT-3101 antibody

businessnewstoday- October 23, 2023

Switzerland-based Roche has officially declared its acquisition agreement for Telavant Holdings, Inc., a Roivant company collaboratively owned by Roivant Sciences Ltd. and Pfizer Inc. The ... Read More

Bristol Myers Squibb to acquire Mirati Therapeutics in $4.8bn deal

businessnewstoday- October 9, 2023

Bristol Myers Squibb (NYSE: BMY) is set to acquire Mirati Therapeutics, Inc. (NASDAQ: MRTX) at $58.00 per share in a cash deal valued at $4.8 ... Read More

Eli Lilly announces $1.4bn acquisition of POINT Biopharma in radiopharmaceutical domain

businessnewstoday- October 3, 2023

Eli Lilly and Company (NYSE: LLY) is set to acquire POINT Biopharma Global, Inc. (NASDAQ: PNT), a leading radiopharmaceutical firm, marking a significant leap in ... Read More

Viatris Inc. announces divestitures in key business sectors: Comprehensive breakdown

businessnewstoday- October 2, 2023

Viatris Inc. (NASDAQ: VTRS), a frontrunner in global healthcare, has unveiled a series of divestitures in its business framework. Leading the announcements, Viatris is set ... Read More

Bausch + Lomb completes XIIDRA acquisition to fortify dry eye offering

businessnewstoday- October 1, 2023

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a prominent global eye health company, has successfully wrapped up its acquisition of XIIDRA (lifitegrast ophthalmic solution) 5%. XIIDRA ... Read More